(All times are CDT)

Tuesday, September 15

8:00 – 8:20 a.m.  Keynote Address: Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19: The Research Response

8:30 a.m. – 12:00 p.m. and 1:00 – 5:00 p.m. Invited Speakers

Understanding SARS-CoV-2: Virology, Epidemiology, and Pathogenesis

  • Susan Weiss, Ph.D., Professor and Vice Chair, Department of Microbiology
    Co-Director, Penn Center for Research on Coronaviruses and Other Emerging Pathogens
    Perelman School of Medicine, University of Pennsylvania
    Overview of Coronaviruses
  • Linfa Wang, Ph.D., Director of the Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore
    Zoonotic Origins: Why bats?
  • Tom Gallagher, Ph.D., Professor of Microbiology and Immunology, Loyola University Chicago
    Virus Entry and Targets
  • Jason McLellan, Ph.D.
    Structure and Design of SARS-CoV-2 Spikes
  • Dan Barouch, M.D., Ph.D., William Bosworth Castle Professor of Medicine and Professor of Immunology at Harvard Medical School, Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center

Investigating SARS-CoV-2: Animal Models and Assays

  • Vincent Munster, Ph.D., Chief, Virus Ecology Unit, National Institute of Allergy and Infectious Diseases (NIAID)
    Primate Models for SARS-CoV-2
  • Paul McCray, M.D., Professor of Pediatrics, Microbiology and Immunology, and Internal Medicine, University of Iowa
    Rodent Models for SARS-CoV-2
  • Janice Chen, Ph.D., Co-founder and CTO, Mammouth Biosciences
    Diagnostic Approaches
  • Stanley Perlman, M.D., Ph.D., Professor of Microbiology and Immunology, Professor of Pediatrics, Mark Stinski Chair in Virology, University of Iowa
    Host Immune Response to CoVs: Friend or Foe?
  • Galit Alter, Ph.D., Professor of Medicine at Harvard Medical School, Group Leader at the Ragon Institute of MGH, MIT and Harvard
    Humoral Immune Response

Treatment and Prevention of COVID-19: Vaccines and Therapeutic Interventions

  • Mark Denison, M.D.Edward Claiborne Stahlman Professor of Pediatrics, Professor of Pathology, Microbiology and Immunology, and Director of the Division of Pediatric Infectious Diseases at Vanderbilt University Medical Center
    SARS-CoV-2 Proteins as Targets for Therapies
  • Michael Joyner, M.D., Anesthesiologist, Mayo Clinic
    Convalescent Plasma Therapy
  • Larry Corey, M.D., Past President and Director, Professor in the Vaccine and Infectious Disease Division, Principal Investigator in the  HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center; Professor of Medicine and Laboratory Medicine, University of Washington
    Strategies for Vaccine Development​
  • Florian Krammer, Ph.D., Professor of Vaccinology, Icahn School of Medicine at Mount Sinai
    Vaccine Readouts: Analysis, Antibodies, and Immune Response
  • Kizzmekia Corbett, Ph.D., Research Fellow in the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID)
    NIH VRC Efforts and RNA Vaccine Candidates
  • Sarah Gilbert, Professor of Vaccinology, Nuffield Department of Medicine, University of Oxford; Co-founder of Vaccitech
    Adenovirus Vaccine Candidates

Wednesday, September 16

Abstract Presentations

The second day of programming will primarily be comprised of oral presentations of abstracts submitted to ASGCT during the Call for Abstracts. These abstracts will consist of brand new research relating to COVID-19 on topics such as diagnostics, vaccine strategies, and gene and cell therapies. 

Sponsored Lunch and Evening Sessions are planned - If you're interested in participating in a session, please contact Laura Otto, Director of Engagement, for more information.


ASGCT Policy Summit

September 23-25, 2020